FDA Class II recall: one distributor's carbamazepine 200 mg tablets, for black specks

The FDA enforcement report lists a Class II recall, dated 26 August 2026 and still ongoing, of carbamazepine 200 mg tablets in 100- and 1,000-count bottles distributed by Golden State Medical Supply. The reason given is deviation from good manufacturing practice: tablets with black specks.

A Class II recall means use may cause temporary or medically reversible harm, or that serious harm is remote. It concerns specific US-distributed lots, not carbamazepine generally, and there is no new safety signal for the drug.

The practical point for patients on carbamazepine is supply continuity: an abrupt switch or gap in an antiseizure drug is the real risk, not the specks.

• This recall concerns specific US lots from one distributor; there is no new safety finding for carbamazepine
• Do not stop carbamazepine abruptly because of a recall notice
• If a patient's supply is affected, replace with the same drug and formulation
• Ask patients to report tablets that look unusual to their pharmacist

Why it matters

A recall notice can prompt patients to stop an antiseizure drug, which is more dangerous than the defect.

Don't overread it

A Class II manufacturing recall is a quality finding, not evidence that carbamazepine is unsafe.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.